文献速递毛发、甲与色素性疾病

局部芦可替尼治疗白癜风超应答的预测因素与临床影响:都灵白癜风登记处真实世界队列研究

Predictors and clinical impact of super-response in vitiligo patients treated with topical ruxolitinib: A real-world cohort study from a Turin Vitiligo Registry.
PubMed 文献 · J Am Acad Dermatol · 2026-08-28

该回顾性单中心队列研究纳入非节段性白癜风患者,评估局部芦可替尼1.5%乳膏单用或联合治疗的应答。约25%患者为超应答者,基线VSAS是超应答的唯一独立预测因素,超应答者基线疾病活动度与严重度更低、病程更短、肢端/远端受累更少。

要点

  • 约25%患者为超应答者,各治疗组比例相似。
  • 基线VSAS是超应答的唯一独立预测因素。
  • 超应答者基线疾病活动度低、病程短、肢端受累少。

核心结论

  • 局部芦可替尼治疗非节段性白癜风可产生进行性临床改善。
  • 基线VSAS较低可识别更可能实现早期超应答的患者。

研究设计与样本

  • 回顾性单中心队列研究,纳入非节段性白癜风患者。
  • 患者接受局部芦可替尼1.5%乳膏单用或联合治疗。
  • 评估时间点为基线、3个月(T1)和6个月(T2)。
  • 超应答定义为T1时同时达到F-VASI75和T-VASI50。

主要发现

  • 约25%患者为超应答者,各治疗组比例相似。
  • 超应答者基线疾病活动度和严重度更低、病程更短、肢端/远端受累更少。
  • 基线VSAS是超应答的唯一独立预测因素。
  • 患者整体复色和疾病活动度进行性改善,面部病变应答更佳。

关键数值与推荐

  • 超应答定义:T1时同时达到F-VASI75和T-VASI50。

临床怎么用

  • 基线VSAS可用于识别更可能早期超应答的患者,辅助个体化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Response to topical ruxolitinib in nonsegmental vitiligo is heterogeneous, and early predictors of repigmentation may help personalize treatment. OBJECTIVE: To identify baseline predictors of super-response to topical ruxolitinib 1.5% cream and evaluate the association between early and subsequent clinical outcomes. METHODS: We conducted a retrospective, single-center cohort study of patients with nonsegmental vitiligo treated with topical ruxolitinib 1.5% cream as monotherapy or in combination with concomitant therapies. Assessments were performed at baseline, 3 months (T1), and 6 months (T2). Super-responders were defined as patients achieving both F-VASI75 and T-VASI50 at T1. Baseline predictors were evaluated using multivariable logistic regression. RESULTS: Approximately 25% of patients were super-responders, with similar rates across treatment groups. Super-responders had lower baseline disease activity and severity, shorter disease duration, and less frequent acral/distal involvement. Baseline Vitiligo Signs of Activity Score (VSAS) was the only independent predictor of super-response. Overall, patients showed progressive improvement in repigmentation and disease activity, with greater responses in facial lesions. CONCLUSIONS: Topical ruxolitinib produced progressive clinical improvement. Lower baseline disease activity, measured by VSAS, identified patients more likely to achieve an early super-response and may help guide personalized treatment strategies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Fiasconaro CA, Leo F, Cangialosi L, et al. Predictors and clinical impact of super-response in vitiligo patients treated with topical ruxolitinib: A real-world cohort study from a Turin Vitiligo Registry. J Am Acad Dermatol. 2026. PMID: 42665024. doi:10.1016/j.jaad.2026.08.091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。